Generation Bio Co
Company Profile
Business description
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Contact
301 Binney Street
CambridgeMA02142
USAT: +1 617 655-7500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
115
Stocks News & Analysis
stocks
Westpac earnings: Tech overhaul is costly but not hurting lending and deposit growth
stocks
Berkshire Hathaway earnings: Cash balances hit $358 billion on mostly solid results across the firm
Morningstar Investment Ideas
Markets
Index  | Last price  | Change  | % Change  | 
|---|---|---|---|
| All Ordinaries | 9,174.00 | 15.50 | 0.17% | 
| CAC 40 | 8,109.79 | 11.28 | -0.14% | 
| DAX 40 | 24,132.41 | 174.11 | 0.73% | 
| Dow JONES (US) | 47,336.68 | 226.19 | -0.48% | 
| FTSE 100 | 9,701.37 | 15.88 | -0.16% | 
| HKSE | 26,158.36 | 251.71 | 0.97% | 
| NASDAQ | 23,834.72 | 109.77 | 0.46% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,586.23 | 29.93 | 0.22% | 
| S&P 500 | 6,851.97 | 11.77 | 0.17% | 
| S&P/ASX 200 | 8,882.70 | 24.10 | 0.27% | 
| SSE Composite Index | 3,976.52 | 21.73 | 0.55% |